Biodexa Pharmaceuticals
BDRX
4 hedge funds and large institutions have $28.1K invested in Biodexa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
300% more funds holding
Funds holding: 1 → 4 (+3)
1.94% more ownership
Funds ownership: 1.25% → 3.19% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$40.6K |
| 2 |
GAMMA Investing
Foster City,
California
|
+$5.6K |
| 3 |
Morgan Stanley
New York
|
+$2.8K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.4K |
Top Sellers
BDRX Hedge Fund Activity: Q1 2025 in Review
4 of the 7,492 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2025, worth a combined $28.1K — down 4.1% from $29.3K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BDRX positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $40.6K.
- 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2025, up from 1 in Q4 2024.
- Funds reported $28.1K of Biodexa Pharmaceuticals stock for Q1 2025, down 4.1% quarter-over-quarter.
- 3 funds opened new Biodexa Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest Biodexa Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $40.6K added.
Based on aggregated 13F filings for Q1 2025.